Publications by authors named "Denis Ravel"

Claim this Profile
L
Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer's Disease and Down Syndrome.
Laurent Meijer, Emilie Chrétien, Denis Ravel

J Alzheimers Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
Philippe Damier, Bertrand Degos, Giovanni Castelonovo, Mathieu Anheim, Isabelle Benatru, Denis Ravel

Mov Disord· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics.
Christina Georgoula, Maite Ferrin, Bozena Pietraszczyk-Kedziora, Amaia Hervas, Stéphane Marret, Denis Ravel

Child Psychiatry Hum Dev· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies.
Joaquin Fuentes, Mara Parellada, Christina Georgoula, Guiomar Oliveira, Stéphane Marret, Denis Ravel

Autism Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
Véronique Crutel, Estelle Lambert, Pierre-François Penelaud, Cristina Albarrán Severo, Joaquin Fuentes, Denis Ravel

J Autism Dev Disord· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
Véronique Crutel, Estelle Lambert, Pierre-François Penelaud, Cristina Albarrán Severo, Joaquin Fuentes, Denis Ravel

J Autism Dev Disord· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.
Laurent Meijer, Deborah J Nelson, Vladimir Riazanski, Aida G Gabdoulkhakova, Geneviève Hery-Arnaud, Denis Ravel

J Innate Immun· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.
Florence Meyer-Losic, Céline Nicolazzi, Jérôme Quinonero, Fabien Ribes, Matthieu Michel, Denis Ravel

Clin Cancer Res· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.
Denis Ravel, Vincent Dubois, Jérôme Quinonero, Florence Meyer-Losic, Jeanpierre Delord

Clin Cancer Res· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules.
Catherine De Coupade, Antonio Fittipaldi, Vanessa Chagnas, Matthieu Michel, Sophie Carlier, Denis Ravel

Biochem J· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of sulfonylureas on K(ATP) channel-dependent vasodilation.
Fatima Z G A Cyrino, Daniel A Bottino, Flavio C Coelho, Denis Ravel, Eliete Bouskela

J Diabetes Complications· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of sulphonylureas on the vasodilatory response evoked by K(ATP) channel openers.
Denis Ravel, Nigel Levens, Michel Félétou, Gervais Néliat, Jean Auclair

Fundam Clin Pharmacol· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of benfluorex on fatty acid and glucose metabolism in isolated rat hepatocytes: from metabolic fluxes to gene expression.
Claude Kohl, Denis Ravel, Jean Girard, Jean-Paul Pégorier

Diabetes· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis